248 related articles for article (PubMed ID: 27363398)
41. The effect of levodopa on the habituation of the acoustic-palpebral reflex in Parkinson's disease.
Rey RD; Garretto NS; Bueri JA; Simonetti DD; Sanz OP; Sica RE
Electromyogr Clin Neurophysiol; 1996 Sep; 36(6):357-60. PubMed ID: 8891475
[TBL] [Abstract][Full Text] [Related]
42. Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson's disease dementia.
Vidal EI; Fukushima FB; Valle AP; Villas Boas PJ
J Am Geriatr Soc; 2013 Jan; 61(1):170-2. PubMed ID: 23311565
[No Abstract] [Full Text] [Related]
43. Polyneuropathy in levodopa-treated Parkinson's patients.
Szadejko K; Dziewiatowski K; Szabat K; Robowski P; Schinwelski M; Sitek E; Sławek J
J Neurol Sci; 2016 Dec; 371():36-41. PubMed ID: 27871444
[TBL] [Abstract][Full Text] [Related]
44. Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias.
Bachmann CG; Zapf A; Brunner E; Trenkwalder C
Eur J Neurol; 2009 Aug; 16(8):895-901. PubMed ID: 19374662
[TBL] [Abstract][Full Text] [Related]
45. Levodopa may modulate specific speech impairment in Parkinson's disease: an fMRI study.
Mračková M; Mareček R; Mekyska J; Košťálová M; Rektorová I
J Neural Transm (Vienna); 2024 Feb; 131(2):181-187. PubMed ID: 37943390
[TBL] [Abstract][Full Text] [Related]
46. Improvement in Language Function Correlates with Gait Improvement in Drug-naïve Parkinson's Disease Patients Taking Dopaminergic Medication.
Murakami H; Momma Y; Nohara T; Mori Y; Futamura A; Sugita T; Ishigaki S; Katoh H; Kezuka M; Ono K; Miller MW; Kawamura M
J Parkinsons Dis; 2016; 6(1):209-17. PubMed ID: 26889633
[TBL] [Abstract][Full Text] [Related]
47. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.
Hauser RA; Ellenbogen AL; Metman LV; Hsu A; O'Connell MJ; Modi NB; Yao HM; Kell SH; Gupta SK
Mov Disord; 2011 Oct; 26(12):2246-52. PubMed ID: 21755537
[TBL] [Abstract][Full Text] [Related]
48. Using Spontaneous Eye-blink Rates to Predict the Motor Status of Patients with Parkinson's Disease.
Iwaki H; Sogo H; Morita H; Nishikawa N; Ando R; Miyaue N; Tada S; Yabe H; Nagai M; Nomoto M
Intern Med; 2019; 58(10):1417-1421. PubMed ID: 31092772
[TBL] [Abstract][Full Text] [Related]
49. Motor fluctuations in levodopa treatment: clinical pharmacology.
Stocchi F; Bonamartini A; Vacca L; Ruggieri S
Eur Neurol; 1996; 36 Suppl 1():38-42. PubMed ID: 8791020
[TBL] [Abstract][Full Text] [Related]
50. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.
Chang FC; Kwan V; van der Poorten D; Mahant N; Wolfe N; Ha AD; Griffith JM; Tsui D; Kim SD; Fung VS
J Clin Neurosci; 2016 Mar; 25():41-5. PubMed ID: 26777085
[TBL] [Abstract][Full Text] [Related]
51. Levodopa reinstates connectivity from prefrontal to premotor cortex during externally paced movement in Parkinson's disease.
Herz DM; Siebner HR; Hulme OJ; Florin E; Christensen MS; Timmermann L
Neuroimage; 2014 Apr; 90():15-23. PubMed ID: 24269570
[TBL] [Abstract][Full Text] [Related]
52. New treatments for the motor symptoms of Parkinson's disease.
Vijverman AC; Fox SH
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):761-77. PubMed ID: 25318835
[TBL] [Abstract][Full Text] [Related]
53. Effects of intensive voice treatment (the Lee Silverman Voice Treatment [LSVT]) on vowel articulation in dysarthric individuals with idiopathic Parkinson disease: acoustic and perceptual findings.
Sapir S; Spielman JL; Ramig LO; Story BH; Fox C
J Speech Lang Hear Res; 2007 Aug; 50(4):899-912. PubMed ID: 17675595
[TBL] [Abstract][Full Text] [Related]
54. Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications.
Sossi V; de la Fuente-Fernández R; Schulzer M; Adams J; Stoessl J
Brain; 2006 Apr; 129(Pt 4):1050-8. PubMed ID: 16476675
[TBL] [Abstract][Full Text] [Related]
55. Intonation and speech rate in Parkinson's disease: general and dynamic aspects and responsiveness to levodopa admission.
Skodda S; Grönheit W; Schlegel U
J Voice; 2011 Jul; 25(4):e199-205. PubMed ID: 21051196
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of speech impairment in early stages of Parkinson's disease: a prospective study with the role of pharmacotherapy.
Rusz J; Cmejla R; Růžičková H; Klempíř J; Majerová V; Picmausová J; Roth J; Růžička E
J Neural Transm (Vienna); 2013 Feb; 120(2):319-29. PubMed ID: 22772465
[TBL] [Abstract][Full Text] [Related]
57. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
Goetz CG; Stebbins GT; Blasucci LM
Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
[TBL] [Abstract][Full Text] [Related]
58. Effect of levodopa on both verbal and motor representations of action in Parkinson's disease: a fMRI study.
Péran P; Nemmi F; Méligne D; Cardebat D; Peppe A; Rascol O; Caltagirone C; Demonet JF; Sabatini U
Brain Lang; 2013 Jun; 125(3):324-9. PubMed ID: 22841350
[TBL] [Abstract][Full Text] [Related]
59. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours.
Lhommée E; Klinger H; Thobois S; Schmitt E; Ardouin C; Bichon A; Kistner A; Fraix V; Xie J; Aya Kombo M; Chabardès S; Seigneuret E; Benabid AL; Mertens P; Polo G; Carnicella S; Quesada JL; Bosson JL; Broussolle E; Pollak P; Krack P
Brain; 2012 May; 135(Pt 5):1463-77. PubMed ID: 22508959
[TBL] [Abstract][Full Text] [Related]
60. When do levodopa motor fluctuations first appear in Parkinson's disease?
Stocchi F; Jenner P; Obeso JA
Eur Neurol; 2010; 63(5):257-66. PubMed ID: 20332641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
